Search Results

Press Releases

Andelyn Biosciences Expands AAV Curator™ Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and Harvard

February 19, 2025

·

3 min read

Press Releases

Bioz Badges Highlight the Broad Applications of Chondrex Products

January 14, 2025

·

3 min read

Business

Bayer and Broad Institute extend cancer therapy research collaboration

Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology candidates.

November 2, 2023

·

3 min read

Approvals

GSK Wins Broad Label Expansion for Jemperli in First-Line Endometrial Cancer

In pursuit of Merck’s blockbuster Keytruda, GSK’s Jemperli scored its own broad FDA label expansion, allowing its use in first-line endometrial cancer regardless of biomarker status.

August 2, 2024

·

2 min read

·

Tristan Manalac

Press Releases

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

February 10, 2025

·

3 min read

Press Releases

LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population

February 10, 2025

·

4 min read

Pharm Country

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well.

May 6, 2024

·

8 min read

Business

Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies

Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.

November 2, 2023

·

4 min read

Drug Development

Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, announced that it has completed enrollment in its Phase 1 trial with OVX033, the company’s broad-spectrum vaccine candidate against sarbecoviruses.

June 25, 2024

·

3 min read

Press Releases

Silq Technologies Corp. and NuSil Technology LLC Announce Collaboration Agreement to Drive Broad-based Adoption of Silq’s Novel Surface Treatment Technology

February 19, 2025

·

3 min read